TEM Rebounds on "Xm" News: Can Stock Return to $70?
Tempus AI surged over 8% intraday against the market trend after the company launched Xm, a test designed to monitor immunotherapy responses in patients with advanced cancer. TEM's stock price fell 20% last week after being targeted by a short report from Spruce Point. The report raised serious concerns about the integrity of Tempus AI's products, the credibility of its management team, and its financial reporting practices. ------- How do you view the rally after the short report? Did you buy the dip last week? Will you sell to take profit now or hold?
+ Follow
+1